Wall Street analysts expect Novartis (NVS) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year decline of 7.5%. Revenues are expected to be $13.56 billion, up 2.5% from the year-ago quarter.<\/p>\n
The consensus EPS estimate for the quarter has been revised 1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.<\/p>\n
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.<\/p>\n
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts’ forecasts for certain key metrics often provides a more comprehensive understanding.<\/p>\n
Bearing this in mind, let’s now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.<\/p>\n
The consensus among analysts is that ‘Revenues- Oncology- Tafinlar + Mekinist- Total’ will reach $555.25 million. The estimate suggests a change of +0.6% year over year.<\/p>\n
It is projected by analysts that the ‘Revenues- Other revenues’ will reach $459.04 million. The estimate points to a change of +18.6% from the year-ago quarter.<\/p>\n
The combined assessment of analysts suggests that ‘Revenues- Oncology- Kisqali- Total’ will likely reach $1.47 billion. The estimate indicates a change of +54% from the prior-year quarter.<\/p>\n
Analysts expect ‘Revenues- Immunology- Cosentyx- Total’ to come in at $1.65 billion. The estimate suggests a change of +7.5% year over year.<\/p>\n
According to the collective judgment of analysts, ‘Revenues- Oncology- Tasigna- US’ should come in at $39.24 million. The estimate indicates a year-over-year change of -80.1%.<\/p>\n
Analysts forecast ‘Revenues- Oncology- Promacta\/Revolade- US’ to reach $58.23 million. The estimate suggests a change of -79.8% year over year.<\/p>\n
Based on the collective assessment of analysts, ‘Revenues- Immunology- Cosentyx- US’ should arrive at $891.17 million. The estimate points to a change of +9.4% from the year-ago quarter.<\/p>\n
The collective assessment of analysts points to an estimated ‘Revenues- Cardiovascular- Entresto- US’ of $220.89 million. The estimate points to a change of -81.1% from the year-ago quarter.<\/p>\n
Analysts predict that the ‘Revenues- Oncology- Tasigna- ROW’ will reach $121.70 million. The estimate suggests a change of -32.4% year over year.<\/p>\n
The consensus estimate for ‘Revenues- Oncology- Tafinlar + Mekinist- ROW’ stands at $372.67 million. The estimate points to a change of +8.3% from the year-ago quarter.<\/p>\n
Analysts’ assessment points toward ‘Revenues- Oncology- Promacta\/Revolade- ROW’ reaching $161.68 million. The estimate points to a change of -37.3% from the year-ago quarter.<\/p>\n
The average prediction of analysts places ‘Revenues- Immunology- Cosentyx- ROW’ at $757.57 million. The estimate indicates a change of +5.4% from the prior-year quarter.<\/p>\n
View all Key Company Metrics for Novartis here>>><\/p>\n
Over the past month, shares of Novartis have returned -2.3% versus the Zacks S&P 500 composite’s +9.7% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>> .<\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a><\/p>\n Novartis AG (NVS) : Free Stock Analysis Report<\/a><\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n